{"id":"NCT01003990","sponsor":"Bristol-Myers Squibb","briefTitle":"Roll-Over Protocol To Provide Atv And/Or Truvada For Extended Access","officialTitle":"Atazanavir (BMS-232632) for HIV Infected Individuals Completing Atazanavir Clinical Trials: An Extended Access Study","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2002-10","primaryCompletion":"2016-02","completion":"2016-02","firstPosted":"2009-10-29","resultsPosted":"2017-05-11","lastUpdate":"2017-05-11"},"enrollment":710,"design":{"allocation":"NON_RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["HIV"],"interventions":[{"type":"DRUG","name":"Atazanavir","otherNames":["Reyataz","BMS-232632"]},{"type":"DRUG","name":"Atazanavir/Ritonavir","otherNames":["Reyataz","BMS-232632"]},{"type":"DRUG","name":"Tenofovir/Emtricitabine","otherNames":["Truvada"]},{"type":"DRUG","name":"Lopinavir/ritonavir","otherNames":[]}],"arms":[{"label":"Atazanavir","type":"EXPERIMENTAL"},{"label":"Atazanavir/Ritonavir","type":"EXPERIMENTAL"},{"label":"Lopinavir/Ritonavir","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to provide atazanavir or tenofovir-emtricitabine to HIV-infected subjects who have completed atazanavir or tenofovir-emtricitabine therapy on a previous BMS sponsored clinical trial and to collect long-term safety information on the treated population.","primaryOutcome":{"measure":"Number of Participants With Serious Adverse Events (SAEs), Treatment Related SAEs, Treatment Related Adverse Events (AEs), AEs Leading to Discontinuation of Study Therapy, Grade 3 to Grade 4 AEs, Grade 3 to Grade 4 AEs, CDC Class C AIDS Events, or Death","timeFrame":"Date of First Dose to 30 days post the last dose; approximately 405 weeks)","effectByArm":[{"arm":"Atazanavir (ATV)","deltaMin":35,"sd":null},{"arm":"Atazanavir/Ritonavir (ATV/RTV)","deltaMin":19,"sd":null},{"arm":"Lopinavir/Ritonavir (LPV/RTV)","deltaMin":12,"sd":null}],"pValues":[]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":13},"locations":{"siteCount":88,"countries":["United States","Argentina","Brazil","Canada","Chile","Colombia","Costa Rica","Dominican Republic","France","Guatemala","Hungary","Indonesia","Italy","Malaysia","Mexico","Panama","Peru","Portugal","Puerto Rico","Russia","Singapore","South Africa","Spain","Taiwan","Thailand"]},"refs":{"pmids":[],"seeAlso":["http://www.bms.com/studyconnect/Pages/home.aspx","http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"]},"adverseEventsSummary":{"seriousAny":{"events":35,"n":459},"commonTop":["Nasopharyngitis","Upper respiratory tract infection","Diarrhoea","Headache","Influenza"]}}